Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

A survey of practices that treat AYA patients with cancer showed that almost half of them screen for financial hardship, but few offer cancer-specific navigation.

HealthDay News — Artificial intelligence (AI)-based ambient scribes may reduce documentation time and improve physician well-being, according to a study published online Nov. 26 in NEJM AI.

Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer.

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

In this analysis of colorectal cancer patients from 2 clinical trials, researchers aimed to assess the effect of physical activity on overall survival.

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Participants in intervention group reported lower rates of moderate-to-very severe symptoms, including anxiety, depression, pain, fatigue, constipation.

Tanning bed usage was associated with an increased risk of melanoma, at an odds ratio of 2.85, while further analysis revealed a dose–response relationship between the number of tanning bed exposures ...